In rat cortical cultures, nimodipine inhibited calcium fluorescence evoked by 300 nM Bay K8644 with a fitted IC50 of 142.4 nM (n = 12 experiments). At 3 µM, it completely blocked the response to 1.1 µM Bay K8644 but only partly blocked the response to 100 mM K+, indicating that this broader depolarization recruits additional calcium-channel components. [1]
In control and NPC1-mutant human fibroblasts, 6 h exposure to nimodipine at 10 or 50 µM reduced processed SREBP2 on immunoblots. A separate 10 µM, 6 h imaging comparison in mutant fibroblasts did not show clear correction of filipin-based cholesterol-storage staining. These cellular results do not establish correction of NPC1 dysfunction or an in vivo benefit of nimodipine. [2]
Inhibition of agonist-evoked calcium flux
Cell-based study · Primary rat cortical cultures, E18 Sprague–Dawley origin; assay development at DIV11–21 [1]
Nimodipine concentration-dependently suppressed Bay K8644-evoked calcium fluorescence. High-potassium responses were only partly blocked, consistent with contributions from other calcium channel types.
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration–response in Figure 3; 3 µM in Figure 1a control comparison
- Exposure duration
- Methods specifies 30 min compound incubation at room temperature, at 2× final concentration during incubation; fluorescence recording follows aspiration and agonist addition.
- Method
- FLIPR calcium fluorescence in primary cortical cultures; peak change from baseline normalized to assay controls
- Co-treatment
- 300 nM Bay K8644 for Figure 3; Figure 1a uses 1.1 µM Bay K8644 or 100 mM K+ in separate conditions. Network activity suppressed with the reported inhibitor cocktail.
- Reported limits
- Vehicle concentration for these reference-pharmacology curves is not explicitly assigned; DMSO percentages reported for library screening are not borrowed. Figure 3 fitted IC50 has no reported error estimate.
Methods and source locations
Compound reported in the paper: Nimodipine; Compound label in the paper: nimodipine
Compound-level research evidence; no independent validation of a current Adooq lot or enantiomer-specific activity.
Results: Isolation of LTCC-mediated responses; Pharmacology of reference compounds; Figures 1a and 3c–d; Methods: Calcium flux assay, Chemicals, Data analysis
Inhibition of calcium fluorescence evoked by 300 nM Bay K8644 at holding [K+] of 20 mM: Calcium 6 fluorescence; fitted concentration–response. Results identifies IC50; caption calls antagonist fits EC50. No ± is supplied for this fitted value. — Results: Pharmacology of reference compounds; Figure 3c–d and caption
Nimodipine inhibition under two stimulation conditions: Calcium fluorescence; corresponding stimulated controls without nimodipine. No exact inhibition percentage inferred from traces. — Figure 1a, caption and Results: Isolation of LTCC-mediated responses
Voltage-dependent inhibition of neuronal calcium-channel current
Cell-based study · Primary rat cortical neurons, DIV5–14; whole-cell patch clamp with Ba2+ as charge carrier [1]
Nimodipine inhibited neuronal calcium-channel currents with markedly different potency under different holding/test potentials. Selected numeric results exclude the agonist-present curve, whose IC50 differs between narrative and caption.
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration–response curves in Figure 5a; fitted IC50 values are endpoints, not treatment concentrations
- Exposure duration
- Acute perfusion; Methods allows approximately 3 min stabilization in the optimized assay. A separate timing for each no-Bay-K curve is not stated.
- Method
- Whole-cell voltage clamp at room temperature (~22 °C); Ba2+ current recorded in solutions suppressing sodium and potassium currents
- Co-treatment
- Selected curves omit Bay K8644; agonist-present curve and peptide-blocker control experiments are separate conditions.
- Reported limits
- Vehicle percentage and curve-specific exposure times for the selected no-Bay-K protocols are not explicitly specified.
Methods and source locations
Compound reported in the paper: Nimodipine; Compound label in the paper: nimodipine
Compound-level research evidence; no independent validation of a current Adooq lot or enantiomer-specific activity.
Results: Development of a secondary patch clamp assay; Figure 5a,e; Methods: Electrophysiology, Chemicals, Data analysis
No-Bay-K current inhibition at holding/test potentials −50/−20 mV: Whole-cell Ba2+ current; fitted concentration–response; mean ± SEM as specified in Data analysis; compound-free current is control. — Figure 5a caption; Results: Development of a secondary patch clamp assay
No-Bay-K current inhibition at holding/test potentials −90/0 mV: Whole-cell Ba2+ current; mean ± SEM for IC50. Different holding and test potentials; not a single-variable comparison. — Figure 5a caption and Results: Development of a secondary patch clamp assay
SREBP2 processing and cholesterol-storage readouts in fibroblasts
Cell-based study · Human NPC1-mutant GM03123 and control GM05659 fibroblasts; cholesterol-deficient conditions [2]
Nimodipine reduced processed SREBP2 in both fibroblast lines. In NPC1-mutant cells, a separate filipin readout under the same 6 h treatment framework did not show clear correction of cholesterol accumulation.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 and 50 µM for Figure 6C immunoblot; 10 µM for Figure 5E–F imaging
- Exposure duration
- 6 h; Figure 6 cultures first maintained in LPDS medium for 24 h
- Method
- Cell treatment followed by Western blotting or filipin/LAMP1/DRAQ5 imaging in separate readouts
- Co-treatment
- Selected nimodipine-only conditions; lithium comparators are separate. Western method includes ALLN before harvest.
- Reported limits
- Nimodipine vehicle, lot/purity and replication for Figure 6C/5E–F not specified in the relevant captions/methods. SI S4 not retrieved, so the 1 µM claim is not adopted.
Methods and source locations
Compound reported in the paper: Nimodipine; Compound label in the paper: Nimo
Compound-level research evidence; no independent validation of a current Adooq lot or enantiomer-specific activity.
Results: Lithium decreases processed SREBP2 by damping the intracellular Ca2+ level; Figure 6C; Figure 5E–F; STAR Methods: Key resources table, Cells, Western blotting, Filipin/LAMP1/DRAQ5 staining
Processed SREBP2 protein in NPC1WT and NPC1mu fibroblasts: Western blot versus 0 µM control, β-actin loading control; full-length SREBP2 also shown. No exact fold reduction inferred; replicate number for this panel not specified in caption. — Figure 6C image/caption and associated Results
Filipin/DRAQ5 and LAMP1/DRAQ5 signals in NPC1mu fibroblasts: Filipin and LAMP1 imaging with control/Mock comparator; DRAQ5 normalization in Figure 5F. No exact magnitude or statistical equivalence inferred. — Figure 5E–F image/caption